|| powered by |
From a set of formulas to visible changes in liver cancer16.05.2008 - (idw) HepatoSys - Kompetenznetz Systembiologie des Hepatozyten
With systems biology methods, CancerSys investigates molecular- and cell-biological processes in the formation of tumors in the liver
A positive evaluation by a European Union brain-trust set the course for the new research network CancerSys. The consortium addresses itself to the systems biology investigation of liver cancer and is expected to begin work early in 2009. CancerSys evolved from HepatoSys, the Systems Biology Competence Network founded in 2004 for the investigation of liver cells, and will expand its work to an international level of collaboration.
Systems Biology is a young field with the overall aim of creating a holistic picture of dynamic life processes with regard to all levels - from the genome via the proteome and the organisation of the cell organelles all the way to the complete cell or even an entire organism. In doing so, Systems Biology takes into consideration the dynamic interplay of the components involved. In order to achieve this high aspiration, Systems Biology combines quantitative methods used in molecular biology with knowledge gathered in mathematics, informatics and systems science.
The HepatoSys consortium was launched in 2004 as the first large and interdisciplinary network in the field of Systems Biology. Since then, more than 40 research groups all over Germany have applied themselves to the investigation of molecular- and cell-biological processes in the liver cell (hepatocyte). "In the course of the last few years we have laid the foundation for a systems biology investigation of hepatocytes", says CancerSys coordinator Prof. Dr. Jan Hengstler of the University of Dortmund. Computer models for the simulation of signal transmission pathways were developed as well as standardized cell culture conditions and common process specifications to form a base for quantitative analysis of the processes within the cell and also for interdisciplinary collaboration. "On this basis, we can now turn toward more specific questions such as the processes involved in the evolution of liver cancer", explains Dr. Hengstler who has a leading part in the HepatoSys network as the coordinator of the cell biology platform.
CancerSys is aiming at two particular signal paths known to play a role in the development of cancer if they get out of control, namely, the beta-catenin- and the ras-signal paths. Both regulate the reproduction (proliferation) of liver cells and have an influence on their gene activity. The beta-catenin-path is particularly relevant in the center of the lobe of the liver whereas the ras-signals are dominant in the periportal area, i.e. close to the portal vein which is the gateway for blood entering the liver.
The objective of the CancerSys consortium is to construct dynamic models of these two signal paths and their interaction and to then integrate them into a three-dimensional simulation of the liver. "We created mathematical models on the basis of quantitative molecular- and cell-biological tests and then built a bridge from this set of formulas to the visible changes caused by the cancerous process in the liver", Hengstler said, in explaining their research objective. By means of this hitherto unique methodical approach, it is possible to graphically reconstruct which consequences a change - i.e. through gene mutations, viral diseases or toxic substances such as alcohol and certain medications - involves in the network of signal paths and can thus contribute to the development of cancer. Impressive first simulations can be viewed at http://inria.livertumor.hoehme.com.
The CancerSys research project was given the highest possible rating by the European Union brain-trust and is expected to take up work early in 2009. In the first instance, nine project partners with their research groups are participating. Four of them will work experimentally, four will work theoretically and one will work in both modes. Most of the research teams involved are from the HepatoSys consortium as well as from other German systems biology networks. International groups from Europe and the US will also take part. "Not only do we expect substantial progress from the network on the subject of liver cancer," says Hengstler. "CancerSys also signifies an expansion and better visibility for German systems biology research, especially for HepatoSys, on an international level". Thus the activities of CancerSys will have positive effects on Germany as a research location.
About HepatoSys and CancerSys
HepatoSys was founded in 2004 by the Federal Ministry of Education and Research (BMBF) in co-operation with the Project Management Jülich (PtJ). The research groups in this network work on an interdisciplinary consideration of all processes in the liver with special focus on the liver cell (hepatocyte). Scientists coming from completely different fields collaborate closely on computer modelling of the functions of the biological system. The objective is a virtual liver cell which would make it possible to model physiological processes in silico. With the new research network CancerSys, the work of the HepatoSys consortium is being expanded to an international level. Content-wise, CancerSys applies itself to investigating the mechanisms during the evolution of liver cancer.
Contact information for journalists
Dr. Ute Heisner
Hermann - Herder Str. 3
Phone : +49 761 203 5803
Fax : +49 761 203 5967
Prof. Dr. Jan G. Hengstler
IfADo - Leibniz Research Centre
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Competence network's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. HepatoSys undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
HTML-Code zum Verweis auf diese Seite:
<a href="http://www.uni-protokolle.de/nachrichten/id/156632/">From a set of formulas to visible changes in liver cancer </a>